Lexicon - A-Z Guide 2021 S.I. composants mineurs de l’huile de d’ OmeGodevraient contribuer® Références / References saumon OmeGo. Une démons-® à rééquilibrer la réponse immuni- tration supplémentaire du carac- taire inflammatoire dans les infec- (1). Schmid-Schönbein GW. Analysis of inflammation. Annu Rev Biomed Eng 2006; O tère unique de cette huile de nou- tions à COVID-19 et à empêcher 8: 93-131. velle génération. qu’elles ne deviennent graves. (2). Serhan CN. Treating inflammation and infection m in the 21st century: new hints from decoding HBC est également sur le point resolution mediators and mechanisms. Faseb j 2017; 31: 1273-1288. ◗Un engagement majeur de lancer deux essais de phase (3). Hartley A, Haskard D, Khamis R. Oxidized dans la recherche 2 avec OmeGo, une étude sur® LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future clinique pour améliorer l’asthme et une autre sur la directions in diagnosis and therapy. BPCO / le poumon des fumeurs. Trends Cardiovasc Med 2019; 29: 22-26. la santé humaine. (4). Sedgwick JB, Hwang YS, Gerbyshak HA, Kita Les éosinophiles sont des H, Busse WW. Oxidized low-density lipoprotein moteurs importants de l’inflam- activates migration and degranulation of human granulocytes. Am J Respir Cell Mol Biol HBC continue à investir de mation chez jusqu’à 40 % des 2003; 29: 702-709. (5). Rhoads JP, Major AS. How Oxidized Low- manière significative dans la patients atteints de ces patho- Density Lipoprotein Activates Inflammatory R&D afin d’élucider davan- logies. En outre, les patients Responses. Crit Rev Immunol 2018; 38: 333-342. tage les avantages différenciés atteints de BPCO présentent (6). Can U, Yerlikaya FH, Yosunkaya S. Role of d’OmeGopour la santé. Dans le® un stress oxydatif élevé et donc oxidative stress and serum lipid levels in stable chronic obstructive pulmonary disease. J Chin domaine de la santé immunitaire, des niveaux élevés d’oxLDL. Med Assoc 2015; 78: 702-708. la société a lancé des essais de Par conséquent, la modulation (7). Shen Y, Yang T, Guo S, Li X, Chen L, Wang T, Wen F. Increased serum ox-LDL levels phase 2 avec OmeGo dans le® ciblée de la fonction des éosino- correlated with lung function, inflammation, and oxidative stress in COPD. Mediators traitement des adultes atteints de philes par OmeGo, ainsi que ses® Inflamm 2013; 2013: 972347. COVID-19 léger à modéré. Une vastes effets anti-inflammatoires (8). Calder PC. Immunonutrition. Bmj 2003; 327: 117-118. première étude en ambulatoire et antioxydants, semblent consti- (9). Calder PC. Marine omega-3 fatty acids and (NCT04465513) est presque ter- tuer un profil attrayant et très inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta minée, et une étude ultérieure en pertinent pour améliorer poten- 2015; 1851: 469-484. hospitalisation est sur le point de tiellement la santé de ces deux (10). Drouin G, Rioux V, Legrand P. The n-3 docosapentaenoic acid (DPA): A new player in 227 commencer. Les effets généraux groupes de patients. ■ the n-3 long chain polyunsaturated fatty acid family. Biochimie 2019; 159: 36-48. (11). Regidor PA, Mueller A, Sailer M, Gonzalez Santos F, Rizo JM, Egea FM. Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response. Int J Mol Sci 2020; 22. important. For asthma, the targeted health, the company has initiated (12). Bomi Framroze NS. The Effect of Dietary Oil eosinophilic inhibitory action phase 2 trial work with OmeGoin® Capsules on Reducing Serum Concentrations of Oxidized Low Density Lipoprotein- β2- should be especially beneficial. the treatment of adults with mild Glycoprotein-I Complex. Journal of Nutrition & Food Sciences 2013; 03. These elements contained in to moderate COVID-19. An initial (13). Fahy JV. Type 2 inflammation in asthma-- OmeGo that modulate EEF have® outpatient study (NCT04465513) present in most, absent in many. Nat Rev Immunol 2015; 15: 57-65. not been described before and has almost completed, and a (14). Avena-Woods C. Overview of atopic are unique to OmeGo. HBC® subsequent inpatient study is about dermatitis. Am J Manag Care 2017; 23: S115-s123. has filed a US patent application to commence. The broad effects (15). Stevens WW, Schleimer RP, Kern RC. Chronic (630063274 04/07/2020) on these of OmeGoare anticipated to help® Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract 2016; 4: 565-572. minor components in OmeGo® rebalance the immune inflammatory (16). Framroze B, Heggdal H. An in vitro study to salmon oil. A further demonstration response in COVID-19 infections explore the modulation of eosinophil effector function in human allergic peripheral blood of the uniqueness of this next and prevent them from becoming eosinophils using enzymatically extracted generation oil. salmonid oil. Functional Foods in Health and severe. Disease 2020; 10. HBC is also about to initiate two ◗Major commitment to phase 2 trials with OmeGo, one® OmeGo’s targeted modulation® clinical research to study in asthma and another of eosinophil function along enhance human health. in COPD / smokers’ lung. with its broad anti-inflammatory Eosinophils are important drivers and antioxidant effects looks an of inflammation in up to 40% of attractive and highly relevant profile HBC continues to invest patients with these conditions. In to potentially enhance the health of significantly in R&D to further addition, patients with COPD have the two patient groups. ■ elucidate the differentiated health raised oxidative stress and hence benefits of OmeGo. In immune® raised levels of oxLDL. Therefore, News on Functional & Health Ingredients \ Special Issue \ A - Z Health Ingredients 2021 \ ■